Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial

Chest

Volumn 151, Issue 5, 2017, Pages 1069-1080

  Hung, Ivan F N ^a,b   To, Kelvin K W ^a   Chan, Jasper F W ^a   Cheng, Vincent C C ^a   Liu, Kevin S H ^b   Tam, Anthony ^b   Chan, Tuen Ching ^b   Zhang, Anna Jinxia ^a   Li, Patrick ^a   Wong, Tin Lun ^a   Zhang, Ricky ^b   Cheung, Michael K S ^b   Leung, William ^c   Lau, Johnson Y N ^a   Fok, Manson ^a   Chen, Honglin ^a,d   Chan, Kwok Hung ^a   Yuen, Kwok Yung ^a,d  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

A(H3N2); clarithromycin; hospitalized; naproxen; oseltamivir

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CLARITHROMYCIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR;

AGED; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; LENGTH OF STAY; MALE; MORTALITY; NASOPHARYNX; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS LOAD;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; LENGTH OF STAY; MALE; MORTALITY; NAPROXEN; NASOPHARYNX; OSELTAMIVIR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85019156178     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.012     Document Type: Article

References (36)

1. 1 World Health Organization. Influenza (seasonal). http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed March 27, 2016.
2. 2 Centre for Health Protection. Flu Express: local situation of influenza activity (as of July 1, 2015). http://www.chp.gov.hk/files/pdf/fluexpress_web_week26_3_7_2015_eng.pdf. Accessed March 27, 2016.
3. 3 Chen, Y., Liang, W., Yang, S., et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 381:9881 (2013), 1916–1925.
4. 4 To, K.K., Chan, J.F., Chen, H., Li, L., Yuen, K.Y., The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 13:9 (2013), 809–821.
5. 5 Yuen, K.Y., Chan, P.K., Peiris, M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351:9101 (1998), 467–471.
6. 6 Dunning, J., Baillie, J.K., Cao, B., Hayden, F.G., ISARIC, Antiviral combinations for severe influenza. Lancet Infect Dis 14:12 (2014), 1259–1270.
7. 7 Lejal, N., Tarus, B., Bouguyon, E., et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 57:5 (2013), 2231–2242.
8. 8 Sawabuchi, T., Suzuki, S., Iwase, K., et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology 14:8 (2009), 1173–1179.
9. 9 Takahashi, E., Kataoka, K., Indalao, I.L., et al. Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol 86:20 (2012), 10924–10934.
10. 10 Ninomiya, K., Fukui, T., Imai, T., Matsui, M., Matsuoka, K., Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza. J Nippon Med Sch 69:1 (2002), 53–57.
11. 11 To, K.K., Hung, I.F., Li, I.W., et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 50:6 (2010), 850–859.
12. 12 Kim, W.Y., Suh, G.Y., Huh, J.W., et al., the Korean Society of Critical Care Medicine (KSCCM) H1N1 Collaborative. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 55:12 (2011), 5703–5709.
13. 13 Darwish, I., Mubareka, S., Liles, W.C., Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 9:7 (2011), 807–822.
14. 14 Sato, K., Suga, M., Akaike, T., et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 157:3 (1998), 853–857.
15. 15 Zheng, B., Chan, K., Lin, Y., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105:23 (2008), 8091–8096.
16. 16 Yamaya, M., Shinya, K., Hatachi, Y., et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 333:1 (2010), 81–90.
17. 17 Cheng, V.C., To, K.K., Tse, H., Hung, I.F., Yuen, K.Y., Two years after pandemic influenza A/2009/H1N1: what have we learned?. Clin Microbiol Rev 25:2 (2012), 223–263.
18. 18 Cohen, M., Zhang, X.Q., Senaati, H.P., et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J, 10, 2013, 321.
19. 19 Rodvoid, K.A., George, J.M., Yoo, L., Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50:10 (2011), 637–664.
20. 20 Aminoshariae, A., Kulild, J.C., Donaldson, M., Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: an updated systematic review. J Am Dent Assoc 147:2 (2016), 98–110.
21. 21 To, K.K., Chan, K.H., Li, I.W., et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol 82:1 (2010), 1–7.
22. 22 Li, I.W., Hung, I.F., To, K.K., et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 137:4 (2010), 759–768.
23. 23 Hassan-Alin, M., Andersson, T., Niazi, M., et al. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther 44:3 (2006), 119–127.
24. 24 Hung, I.F., To, K.K., Lee, C.K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52:4 (2011), 447–456.
25. 25 Hung, I.F., To, K.K., Lee, C.K., et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144:2 (2013), 464–473.
26. 26 Wong, H.K., Lee, C.K., Hung, I.F., et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion 50:9 (2010), 1967–1971.
27. 27 Ishii, H., Komiya, K., Yamagata, E., et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 64:3 (2012), 343–345.
28. 28 Kakeya, H., Seki, M., Izumikawa, K., et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One, 9(3), 2014, e91293.
29. 29 Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2:5 (2014), 395–404.
30. 30 Meijer, A., Rebelo-de-Andrade, H., Correia, V., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 110 (2014), 31–41.
31. 31 Chen, H., Cheung, C.L., Tai, H., et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 15:12 (2009), 1970–1972.
32. 32 Chen, H., Wen, X., To, K.K., et al. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis 201:10 (2010), 1517–1521.
33. 33 Tse, H., To, K.K., Wen, X., et al. Clinical and virological factors associated with viremia in pandemic influenza A/H1N1/2009 virus infection. PLoS One, 6(9), 2011, e22534.
34. 34 Deng, Y.M., Caldwell, N., Hurt, A., et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 90:1 (2011), 87–91.
35. 35 Eshaghi, A., Duvvuri, V.R., Li, A., et al. Genetic characterization of seasonal influenza A (H3N2) viruses in Ontario during 2010-2011 influenza season: high prevalence of mutations at antigenic sites. Influenza Other Respir Viruses 8:2 (2014), 250–257.
36. 36 Deyde, V.M., Okomo-Adhiambo, M., Sheu, T.G., et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 81:1 (2008), 16–24.